Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

NCT04454437 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04454437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04454437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 23, 2020
Completion date
December 31, 2027
Enrollment
80 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple-negative breast cancer